LatestEarly Trial Results Show Promise for Safer Alzheimer's Drug Approach
Health

Early Trial Results Show Promise for Safer Alzheimer's Drug Approach

Adam Feuerstein
Early Trial Results Show Promise for Safer Alzheimer's Drug Approach
Alzheimer's Disease
Summary

ProMIS Neurosciences is developing a new amyloid-clearing medication designed to treat Alzheimer's disease more safely than existing options. Early trial results suggest the approach may successfully reduce amyloid buildup in the brain while minimizing potentially dangerous side effects associated with current treatments. Amyloid-beta accumulation is a hallmark of Alzheimer's disease, and safer removal methods could benefit thousands of patients at risk for cognitive decline. These preliminary findings represent an important step toward improving treatment options for this progressive neurodegenerative condition that affects memory and cognitive function.

Stat News

Originally published on

STAT News

By Adam Feuerstein

Read full article(opens in new tab)

Fetched: July 28, 2026 at 10:00 AM

Related News

More news you might be interested in

View all
Genetic risk factors of fibromyalgia identified in largest study of its kind
Health
Fibromyalgia

Genetic risk factors of fibromyalgia identified in largest study of its kind

Researchers at King's College London have identified new genetic risk factors for fibromyalgia syndrome in a landmark study published in Nature Medicine. The groundbreaking research demonstrates that the nervous system plays a crucial role in the development of this chronic condition. These findings could lead to better understanding of fibromyalgia's underlying biological mechanisms and potentially improve diagnostic and treatment approaches. This largest study of its kind represents significant progress in unraveling the genetic basis of a condition that affects millions worldwide, offering hope for more targeted therapies in the future.

2 hours ago
Medical Xpress
HIV Progress in 'Real Danger' as Global Funding Plummets
Health
HIV/AIDS

HIV Progress in 'Real Danger' as Global Funding Plummets

AIDS experts are warning that the fight against HIV faces a critical crisis despite unprecedented scientific advances. Global funding for HIV programs fell by 20% last year, representing a dangerous setback in prevention and treatment efforts. While medical breakthroughs have improved outcomes for patients with HIV, reduced funding threatens access to antiretroviral therapies, testing, and prevention programs worldwide. Experts emphasize that without adequate financial support, the gains made in recent decades could be reversed, particularly in low and middle-income countries.

3 hours ago
Medical Xpress
PMOS Awareness Growing Among Black and Latina Women With New Diagnosis Hope
Health

PMOS Awareness Growing Among Black and Latina Women With New Diagnosis Hope

A painful endocrine disorder previously known as PCOS is now being called PMOS, bringing renewed attention to a condition that disproportionately affects women of color. Black and Latina women experience higher prevalence rates but historically receive fewer diagnoses, leading to delayed treatment and management. This naming change and increased awareness represents a significant opportunity to improve health outcomes for underrepresented populations. Early recognition and diagnosis are crucial for managing symptoms and preventing long-term complications. Healthcare providers and patients should familiarize themselves with PMOS to ensure equitable care across all communities.

3 hours ago
STAT News
Opinion: Dementia Finally Has a Business Model
Health
Alzheimer's Disease

Opinion: Dementia Finally Has a Business Model

According to medical expert Jason Karlawish, a major economic shift was highlighted at the recent Alzheimer's Association International Conference in London: dementia now has a viable business model. This development signals increased pharmaceutical and healthcare industry investment in dementia treatments and research. The business model emerging around dementia could accelerate drug development and expand treatment options for patients. This economic momentum may also drive innovation and improve accessibility to new therapies for those suffering from cognitive decline and neurodegenerative conditions.

3 hours ago
STAT News